Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TumorSelect Paclitaxel
- Development stage
- Unknown
- Lead developer
- Cloaked Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
**TumorSelect Paclitaxel** is a targeted formulation of the taxane chemotherapy agent paclitaxel, designed for tumor-selective delivery to enhance efficacy and reduce systemic toxicity. Paclitaxel stabilizes microtubules, preventing depolymerization and disrupting mitotic spindle function, leading to G2/M phase arrest and apoptosis in rapidly dividing cancer cells. Developed as a novel delivery system, it aims to concentrate the drug at the tumor site for improved therapeutic outcomes in solid tumors.
- Brand names
- TumorSelect Paclitaxel
02
Targets
BCL-2 (BCL-2 family)TUBB (Tubulin (alpha and beta subunits))Microtubule
Beyond the preview
Go deeper on TumorSelect Paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TumorSelect Paclitaxel.